Condition: Schizophrenia and Other Psychotic Disorders · Cannabis Use Disorder · Healthy · Sponsor: Yale University
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
This description comes directly from the study's public registry record.
Angerlyk Frytz, MD · 203-974-7822 · angerlyk.frytz@yale.edu
Always discuss trial participation with your own doctor first.
| Conneticut Mental Health Center | New Haven, Connecticut, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03995121